Skip Navigation


NDT Advance Access originally published online on April 19, 2005
Nephrology Dialysis Transplantation 2005 20(6):1273-1274; doi:10.1093/ndt/gfh838
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/6/1273    most recent
gfh838v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Matsushita, K.
Right arrow Articles by Umemura, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsushita, K.
Right arrow Articles by Umemura, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Letter

Lobular membranoproliferative glomerulonephritis with organized microtubular monoclonal immunoglobulin deposits associated with B cell small lymphocytic lymphoma

The first 10% of the full text of this article appears below.

Sir,

Fibrillary glomerulonephritis (FGN) and immunotactoid glomerulopathy (ITG) are well known glomerular diseases with Congo-red-negative deposits [1–4]. While FGN is characterized by randomly arranged microfibrils around 20 nm in diameter with no underlying systemic disorder, ITG is defined by orderly arranged microtubular deposits, usually >30 nm in diameter with a hollow core; patients with ITG tend to have underlying lymphoproliferative diseases.

. . . [Full Text of this Article]

Kei Matsushita1, Kiyotaka Nagahama2, Yoshiaki Inayama2, Katsumichi Fujimaki3, Kouichi Tamura1, Nobuhito Hirawa1, Minoru Kihara1, Yoshiyuki Toya1, Machiko Yabana1, Kensuke Joh4 and Satoshi Umemura1

1 Department of Second Internal Medicine2 Department of Pathology3 Department of First Internal Medicine Yokohama City University School of Medicine Kanagawa4 Clinical Research Center Chiba-East National Hospital Chiba Japan Email: umemuras@med.yokohama-cu.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?